These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

270 related items for PubMed ID: 27815915

  • 41. Treatment effect of adalimumab and infliximab in Japanese psoriasis patients: results in a single community-based hospital.
    Noda S, Mizuno K, Adachi M.
    J Dermatol; 2012 Mar; 39(3):265-8. PubMed ID: 22126280
    [Abstract] [Full Text] [Related]

  • 42. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis.
    Menter A, Gordon K, Carey W, Hamilton T, Glazer S, Caro I, Li N, Gulliver W.
    Arch Dermatol; 2005 Jan; 141(1):31-8. PubMed ID: 15655139
    [Abstract] [Full Text] [Related]

  • 43. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION).
    Saurat JH, Stingl G, Dubertret L, Papp K, Langley RG, Ortonne JP, Unnebrink K, Kaul M, Camez A, CHAMPION Study Investigators.
    Br J Dermatol; 2008 Mar; 158(3):558-66. PubMed ID: 18047523
    [Abstract] [Full Text] [Related]

  • 44. A randomized study to evaluate the efficacy and safety of adding topical therapy to etanercept in patients with moderate to severe plaque psoriasis.
    Lebwohl MG, Kircik L, Callis Duffin K, Pariser D, Hooper M, Wenkert D, Thompson EH, Yang J, Kricorian G, Koo J.
    J Am Acad Dermatol; 2013 Sep; 69(3):385-92. PubMed ID: 23643256
    [Abstract] [Full Text] [Related]

  • 45. The real world impact of adalimumab on quality of life and the physical and psychological effects of moderate-to-severe psoriasis: a UK prospective, multicenter, observational study.
    Leman J, Walton S, Layton AM, Ward KA, McBride S, Cliff S, Downs A, Landeira M, Bewley A.
    J Dermatolog Treat; 2020 May; 31(3):213-221. PubMed ID: 30897016
    [Abstract] [Full Text] [Related]

  • 46. Impact of efalizumab on psoriasis-specific patient-reported outcomes. Results from three randomized, placebo-controlled clinical trials of moderate to severe plaque psoriasis.
    Menter A, Kosinski M, Bresnahan BW, Papp KA, Ware JE.
    J Drugs Dermatol; 2004 May; 3(1):27-38. PubMed ID: 14964744
    [Abstract] [Full Text] [Related]

  • 47. Adalimumab in the treatment of moderate-to-severe chronic plaque psoriasis in patients switching from other biologics.
    Sator P, Richter L, Saxinger W, Vasiljevic M, Stingl G.
    J Eur Acad Dermatol Venereol; 2015 Sep; 29(9):1742-9. PubMed ID: 25665143
    [Abstract] [Full Text] [Related]

  • 48. Efficacy and safety of adalimumab in patients with psoriasis previously treated with anti-tumour necrosis factor agents: subanalysis of BELIEVE.
    Ortonne JP, Chimenti S, Reich K, Gniadecki R, Sprøgel P, Unnebrink K, Kupper H, Goldblum O, Thaçi D.
    J Eur Acad Dermatol Venereol; 2011 Sep; 25(9):1012-20. PubMed ID: 21214631
    [Abstract] [Full Text] [Related]

  • 49. Clinical similarity of the biosimilar ABP 501 compared with adalimumab after single transition: long-term results from a randomized controlled, double-blind, 52-week, phase III trial in patients with moderate-to-severe plaque psoriasis.
    Papp K, Bachelez H, Costanzo A, Foley P, Gooderham M, Kaur P, Philipp S, Spelman L, Zhang N, Strober B.
    Br J Dermatol; 2017 Dec; 177(6):1562-1574. PubMed ID: 28755394
    [Abstract] [Full Text] [Related]

  • 50. Adalimumab retreatment successfully restores clinical response and health-related quality of life in patients with moderate to severe psoriasis who undergo therapy interruption.
    Gordon KB, Gottlieb AB, Langely RG, van de Kerkhof P, Belasco KT, Sundaram M, Okun M, Serra L.
    J Eur Acad Dermatol Venereol; 2015 Apr; 29(4):767-76. PubMed ID: 25284275
    [Abstract] [Full Text] [Related]

  • 51. Adalimumab: A Review in Chronic Plaque Psoriasis.
    Burness CB, McKeage K.
    Drugs; 2015 Dec; 75(18):2119-30. PubMed ID: 26586242
    [Abstract] [Full Text] [Related]

  • 52. Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial.
    Feldman SR, Gordon KB, Bala M, Evans R, Li S, Dooley LT, Guzzo C, Patel K, Menter A, Gottlieb AB.
    Br J Dermatol; 2005 May; 152(5):954-60. PubMed ID: 15888152
    [Abstract] [Full Text] [Related]

  • 53. Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: results from an open-label extension study for patients from REVEAL.
    Gordon K, Papp K, Poulin Y, Gu Y, Rozzo S, Sasso EH.
    J Am Acad Dermatol; 2012 Feb; 66(2):241-51. PubMed ID: 21752491
    [Abstract] [Full Text] [Related]

  • 54. Meta-Analyses of Clinical Efficacy of Risankizumab and Adalimumab in Chronic Plaque Psoriasis: Supporting Evidence of Risankizumab Superiority.
    Witjes H, Khatri A, Diderichsen PM, Mandema J, Othman AA.
    Clin Pharmacol Ther; 2020 Feb; 107(2):435-442. PubMed ID: 31502263
    [Abstract] [Full Text] [Related]

  • 55. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial.
    Mease PJ, Gladman DD, Ritchlin CT, Ruderman EM, Steinfeld SD, Choy EH, Sharp JT, Ory PA, Perdok RJ, Weinberg MA, Adalimumab Effectiveness in Psoriatic Arthritis Trial Study Group.
    Arthritis Rheum; 2005 Oct; 52(10):3279-89. PubMed ID: 16200601
    [Abstract] [Full Text] [Related]

  • 56. Ustekinumab improves health-related quality of life in Korean and Taiwanese patients with moderate to severe psoriasis: results from the PEARL trial.
    Tsai TF, Song M, Shen YK, Schenkel B, Choe YB, Kim NI, Lee JH, Lee JH, Song HJ, Youn JI, PEARL investigators.
    J Drugs Dermatol; 2012 Aug; 11(8):943-9. PubMed ID: 22859239
    [Abstract] [Full Text] [Related]

  • 57. Pruritus and quality of life in moderate-to-severe plaque psoriasis: post hoc explorative analysis from the PRISTINE study.
    Mrowietz U, Chouela EN, Mallbris L, Stefanidis D, Marino V, Pedersen R, Boggs RL.
    J Eur Acad Dermatol Venereol; 2015 Jun; 29(6):1114-20. PubMed ID: 25376448
    [Abstract] [Full Text] [Related]

  • 58. Adalimumab in the treatment of psoriasis: pooled efficacy and safety results from three pivotal studies.
    Papp K, Okun M, Vender R.
    J Cutan Med Surg; 2009 Jun; 13 Suppl 2():S58-66. PubMed ID: 19799828
    [Abstract] [Full Text] [Related]

  • 59. Effectiveness of adalimumab in the treatment of scalp and nail affection in patients with moderate to severe plaque psoriasis in routine clinical practice.
    Khobzey K, Liskova I, Szegedi A, Pavlovsky L, Lunder T, Kingo K, Miljković J, Péč J, Bohinc M, Hojnik M.
    Acta Dermatovenerol Alp Pannonica Adriat; 2017 Mar; 26(1):11-14. PubMed ID: 28352929
    [Abstract] [Full Text] [Related]

  • 60. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial.
    Gordon KB, Papp KA, Hamilton TK, Walicke PA, Dummer W, Li N, Bresnahan BW, Menter A, Efalizumab Study Group.
    JAMA; 2003 Dec 17; 290(23):3073-80. PubMed ID: 14679270
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.